IMS-001 is under clinical development by Imstem Biotechnology and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase II drugs for Secondary Progressive Multiple Sclerosis (SPMS) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMS-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMS-001 is under development for the treatment of relapsing-remitting, secondary, and primary progressive forms of multiple sclerosis including neuromyelitis optica spectrum disorder (NMOSD), type 1 diabetes mellitus, acute and chronic GVHD, ARDS due to COVID-19 disease, inflammatory bowel disease, stroke, adrenoleukodystrophy, Duchenne muscular dystrophy, Parkinson's disease unspecified indication. The drug candidate is administered through parenteral and intravenous route. It is a stem cell therapy based on hES-MSCs which includes human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs). It is developed based on T-MSC platform. It was also under development for the treatment of spinal cord injury.
For a complete picture of IMS-001’s drug-specific PTSR and LoA scores, buy the report here.